Targeted Genetics Corp /WA/ - Current report filing (8-K)
18 9월 2007 - 7:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported):
September
17, 2007
Targeted
Genetics Corporation
(Exact
name of registrant as specified in its charter)
Washington
|
|
0-23930
|
|
91-1549568
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1100
Olive Way, Suite 100, Seattle, Washington
|
|
98101
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
|
|
(206) 623-7612
|
Not
Applicable
(Former
name or former address if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 8.01
Other Events.
On
September 17, 2007, Targeted Genetics Corporation, or the Company, announced
the
results of
the
public hearing conducted by the National Institutes of Health (NIH) Recombinant
DNA Advisory Committee, which reviewed the serious adverse event reported by
the
Company surrounding the death of a patient participating in the Company’s Phase
I/II trial of tgAAC94 for inflammatory arthritis.
A
copy of
the press release issued in connection with this announcement is attached as
Exhibit 99.1 to this current report and is incorporated herein by
reference.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits:
|
|
|
99.1
|
|
Press
Release of Targeted Genetics Corporation dated September 17,
2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
TARGETED
GENETICS CORPORATION
|
|
|
|
|
|
|
|
By:
|
/s/
H. STEWART PARKER
|
|
|
H.
Stewart Parker
|
|
|
President
and Chief Executive Officer
|
|
Dated:
September 17, 2007
INDEX
TO EXHIBITS
|
|
|
99.1
|
|
Press
Release of Targeted Genetics Corporation dated September 17,
2007
|
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024